Background: Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-acting antiviral (DAA) treatment in the real-life setting according to Human Immunodeficiency Virus (HIV) coinfection was evaluated. Methods: Patients consecutively enrolled in PITER between April 2014 and June 2019 and with at least 12-weeks follow-up following treatment were analysed. Cox regression analysis were used to evaluate HIV coinfection and factors independently associated with liver disease outcomes following viral eradication in DAA treated patients with pre-treatment liver cirrhosis. Results: 93 HIV/HCV coinfected and 1109 HCV monoinfected patients were evaluated during a median follow-up of 26.7 (range 6-44.6) and 24.6 (range 6.8-...
Our objective was to provide detailed information about the natural history of HIV-hepatitis C virus...
Background. End-stage liver disease (ESLD) is an important cause of morbidity among human immunodef...
On behalf of RIS-HEP13 and GEHEP 011 study groups.[Objective]: To assess the impact of HIV coinfecti...
Background: Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-act...
Background. Few data are available on liver disease progression following viral eradication due to D...
BackgroundThe development of direct-acting antivirals (DAA) for HCV has revolutionized the treatment...
Background: A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarker...
BACKGROUND A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomark...
Background & Aims: HIV/hepatitis B virus (HBV) coinfected subjects are thought to have faster progre...
BackgroundThe incidence and determinants of hepatic decompensation have been incompletely examined a...
Background Human immunodeficiency virus (HIV) coinfection accelerates the rate of liver disease outc...
Human immunodeficiency virus (HIV) infection modifies the natural history of chronic hepatitis C, th...
Our objective was to provide detailed information about the natural history of HIV-hepatitis C virus...
Background. End-stage liver disease (ESLD) is an important cause of morbidity among human immunodef...
On behalf of RIS-HEP13 and GEHEP 011 study groups.[Objective]: To assess the impact of HIV coinfecti...
Background: Liver disease progression after Hepatitis C Virus (HCV) eradication following direct-act...
Background. Few data are available on liver disease progression following viral eradication due to D...
BackgroundThe development of direct-acting antivirals (DAA) for HCV has revolutionized the treatment...
Background: A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomarker...
BACKGROUND A hepatitis C (HCV) cure is associated with changes in lipids and inflammatory biomark...
Background & Aims: HIV/hepatitis B virus (HBV) coinfected subjects are thought to have faster progre...
BackgroundThe incidence and determinants of hepatic decompensation have been incompletely examined a...
Background Human immunodeficiency virus (HIV) coinfection accelerates the rate of liver disease outc...
Human immunodeficiency virus (HIV) infection modifies the natural history of chronic hepatitis C, th...
Our objective was to provide detailed information about the natural history of HIV-hepatitis C virus...
Background. End-stage liver disease (ESLD) is an important cause of morbidity among human immunodef...
On behalf of RIS-HEP13 and GEHEP 011 study groups.[Objective]: To assess the impact of HIV coinfecti...